467 related articles for article (PubMed ID: 30974290)
1. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
3. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
Zhang W; Ba G; Tang R; Li M; Lin H
Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
[TBL] [Abstract][Full Text] [Related]
4. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
5. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke.
Ismael S; Zhao L; Nasoohi S; Ishrat T
Sci Rep; 2018 Apr; 8(1):5971. PubMed ID: 29654318
[TBL] [Abstract][Full Text] [Related]
7. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
Yaw ACK; Chan EWL; Yap JKY; Mai CW
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
[TBL] [Abstract][Full Text] [Related]
8. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
9. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
11. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
12. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
Kammoun HL; Allen TL; Henstridge DC; Barre S; Coll RC; Lancaster GI; Cron L; Reibe S; Chan JY; Bensellam M; Laybutt DR; Butler MS; Robertson AAB; O'Neill LA; Cooper MA; Febbraio MA
Mol Metab; 2018 Apr; 10():66-73. PubMed ID: 29478918
[TBL] [Abstract][Full Text] [Related]
13. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.
Kuemmerle-Deschner JB; Verma D; Endres T; Broderick L; de Jesus AA; Hofer F; Blank N; Krause K; Rietschel C; Horneff G; Aksentijevich I; Lohse P; Goldbach-Mansky R; Hoffman HM; Benseler SM
Arthritis Rheumatol; 2017 Nov; 69(11):2233-2240. PubMed ID: 28692792
[TBL] [Abstract][Full Text] [Related]
15. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
16. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
[TBL] [Abstract][Full Text] [Related]
17. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.
He W; Long T; Pan Q; Zhang S; Zhang Y; Zhang D; Qin G; Chen L; Zhou J
J Neuroinflammation; 2019 Apr; 16(1):78. PubMed ID: 30971286
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 and Potassium Efflux Drive Rapid IL-1β Release from Primary Human Monocytes during
Gov L; Schneider CA; Lima TS; Pandori W; Lodoen MB
J Immunol; 2017 Oct; 199(8):2855-2864. PubMed ID: 28904126
[TBL] [Abstract][Full Text] [Related]
19. Secretion of IL-1β From Monocytes in Gout Is Redox Independent.
Alberts BM; Bruce C; Basnayake K; Ghezzi P; Davies KA; Mullen LM
Front Immunol; 2019; 10():70. PubMed ID: 30761138
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
